Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of Oral ASN51 in Healthy Subjects and Subjects With Alzheimer's Disease

2. Men and women aged 18-55 years, inclusive, at Screening (Part 1) or 55-80 years, inclusive, at Screening (Part 2)

3. Subject must understand the nature of the study and provide signed and dated written informed consent in accordance with local regulations before the conduct of any study-related procedures.

4. Able to complete all study related testing and evaluations

5. Women (Part 1 only) and men of child-bearing potential with partners of child-bearing potential must agree to use highly effective contraception. Contraception should consist of: (1) a condom for the male participant or partner of a female participant, combined with (2) a highly effective method of contraception (e.g., a hormonal method associated with suppression of ovulation, an intrauterine device \[IUD\]) for the female participant or partner of a male participant. Abstinence from heterosexual intercourse should only be used in place of contraception when this is consistent with the usual and preferred lifestyle of the participant. For male subjects, contraception should continue for 90 days after the last dose of investigational medicinal product (IMP, one spermatic cycle). Male subjects should agree to refrain from sperm donation throughout this same period.

6. Women of non-childbearing potential must be post-menopausal (the last menstrual period was at least 12 months ago, and follicle-stimulating hormone \[FSH\] at Screening confirms post-menopausal status), or have no uterus, ovaries, or fallopian tubes (or have their fallopian tubes tied). All women must have a negative pregnancy test result before administration of test article. Women who are surgically sterile must provide documentation of the procedure by an operative report or by ultrasound.

7. Body weight \> 50.0 kg for men and \> 50 kg for women and Body Mass Index (BMI) within the range 18.5-30.0 kg/m2, inclusive.

8. Subject must be, in the opinion of the Investigator, able to participate in all scheduled evaluations, likely to complete all required tests, and likely to be compliant.

9. Subjects is fluent in the local language.

10. Subject agrees not to post any personal medical data related to the study or information related to the study on any website or social media site (e.g., Facebook, Twitter, etc.) until the trial has been completed, this does not include information about participating in a clinical study in general.

11. \[Part 2 only\] Subject is able to undergo Lumbar Puncture (LP)

1. A positive urine drug screen/alcohol breath test at Screening or Day -1.

2. Any history of intellectual disability or psychiatric disorders, including substance use disorders, according to the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) criteria, except a history of mild depression/anxiety that has been resolved for at least the past 12 months.

3. A positive Hepatitis B surface antigen, Hepatitis C antibody, or Human Immunodeficiency Virus (HIV) antibody test at Screening.

4. Alanine aminotransferase or aspartate aminotransferase levels greater than 1.5 times the upper limit of normal (ULN) at Screening or between Screening and first dose administration.

5. Frequent use of any tobacco-containing (e.g., cigar, cigarette, or snuff) or nicotine-containing product (e.g., nicotine chewing gum, nicotine plasters, or other product used for smoking cessation) within 3 months prior to 1 week before study drug administration. Frequent use is defined as more than 10 cigarettes or equivalent per week. Use of any tobacco or nicotine-containing product is prohibited from 1 week prior to study drug administration throughout the study (final visit).

6. History of regular alcohol consumption within the last 12 months, defined as an average weekly intake of \>21 alcoholic drinks/week for men or \>14 alcoholic drinks/week for women.

7. Regularly consumed (e.g., more days than not) excessive quantities of xanthine-containing beverages (e.g., more than five cups of coffee or the equivalent per day) within 30 days prior to Day -1.

8. Received or used an investigational product (including placebo) or device within the following time period prior to Day -1 in the current study: 90 days, 5 half-lives, or twice the duration of the biological effect of the investigational product (whichever is longer).

9. Use of prescription or non-prescription drugs, vitamins, herbal, and dietary supplements (including St John's Wort) within 7 days (or 28 days if the drug is a potential hepatic enzyme inducer) or 5 half-lives (whichever is longer) prior to Day -1.

10. History of clinically significant sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the Investigator or Medical Monitor, contraindicates their participation.

11. Loss of more than 400 mL of blood within 3 months prior to Day -1, i.e., blood donor

12. A positive serum pregnancy test or lactation.

13. Hearing test result considered unacceptable for auditory ERP P300 assessment.

14. A history or presence of any disease, condition, or surgery likely to affect drug absorption, distribution, metabolism, or excretion. Subjects with a history of cholecystectomy should be excluded.

15. A history or presence of a clinically significant hepatic, renal, gastrointestinal, cardiovascular, endocrine, pulmonary, ophthalmologic, immunologic, hematologic, dermatologic, or neurologic abnormality.

16. A clinically significant abnormality on physical examination, neurological examination, electrocardiogram (ECG), or laboratory evaluations at Screening or between Screening and first dose administration.

17. A corrected QT interval measurement corrected according to the Fridericia rule (QTcF) \> 450 msec during controlled rest at screening or between screening and first dose administration, or family history of long QT syndrome.

18. Any clinically significant abnormalities in rhythm, conduction, or morphology of the resting ECG and any abnormalities in the 12-lead ECG that, in the judgement of the Investigator or Medical Monitor, may interfere with the interpretation of QTc interval changes, including abnormal ST-T-wave morphology or left ventricular hypertrophy.

19. PR (PQ) interval shortening \< 120 msec (PR \< 120 msec but \> 110 msec is acceptable if there is no evidence of ventricular pre-excitation).

20. PR (PQ) interval prolongation (\> 220 msec), intermittent second- (Wenckebach block while asleep or in deep rest is not exclusionary) or third-degree AV block.

21. Persistent or intermittent complete bundle branch block (BBB), incomplete bundle branch block (IBBB), or intraventricular conduction delay (IVCD) with QRS \> 120 msec.

22. A clinically significant vital signs abnormality at Screening or Day -1 This includes, but is not limited to, the following, in the sitting position (3 measurements, each 5 minutes apart): (a) systolic blood pressure \< 90 or \>140 mmHg, (b) diastolic blood pressure \< 50 or \> 95 mmHg, or (c) heart rate \< 45 or \> 100 beats per minute.

23. Significant (\> 10%) weight loss or gain within 30 days prior to Day -1

24. A history of seizure.

25. A history of head trauma, with loss of consciousness, except for minor head trauma that occurred at least 20 years prior to first dose.

26. A history of symptomatic orthostatic hypotension (i.e., postural syncope) or symptomatic orthostatic hypotension at Screening.

27. A history of neuroleptic malignant syndrome.

28. A history of chronic urinary tract infections.

29. The subject is, in the opinion of the Investigator or Medical Monitor, unlikely to comply with the protocol or is unsuitable for any reason, e.g., known issues with ability to swallow size 00 capsules.

30. Currently employed by Asceneuron SA or by a clinical trial site participating in this study, or a first-degree relative of an Asceneuron SA employee or of an employee at a participating clinical trial site.

31. Unsatisfactory venous access.

32. Identification of suicide risk in the Columbia-Suicide Severity Rating Scale (C-SSRS).

33. Part 2 only: Abnormal exercise ECG in relation to age.

Part 3 Only:

1. Receipt of any investigational drug or device within 8 weeks or 4 half-lives, whichever is longer, prior to randomization.

2. History of cardiovascular disease or at risk of stroke or heart attack, peripheral vascular intervention, atrial fibrillation, clinically relevant cardiac arrhythmias, or uncontrolled hypertension.

3. History within 2 years of Screening, or current diagnosis of the any of the following psychiatric disorders: Schizophrenia, schizoaffective disorder, bipolar disorder I, or alcohol abuse or dependence per DSM-5 criteria.

4. History of unexplained loss of consciousness, and seizures (excluding infant febrile seizures)

5. Ongoing infectious, metabolic, or systemic diseases affecting the central nervous system (CNS) (e.g. syphilis, untreated hypothyroidism, current vitamin B12 or folate deficiency, potentially clinically significant serum electrolyte disturbances, unstable diabetes mellitus (HbA1c \> 10.5%); or other similar conditions.

6. History within 2 years of Screening, or current diagnosis of a chronic inflammatory disease (i.e., rheumatoid arthritis, systemic lupus, erythematosus, Crohn's disease, etc.).

7. A positive Hepatitis B surface antigen, Hepatitis C antibody, or Human Immunodeficiency Virus (HIV) antibody test at Screening.

8. The subject has received active amyloid or tau immunization at any time, or passive immunization within 12 months of Screening.

9. Intake of any of the prohibited medications listed below within the past 30 days or 5 half-lives, whichever is longer. Subjects need to stay off the medication during the trial.

* For memantine, a 1-month drug-free period is required between the last dose received and Screening

* Anticonvulsants

* Neuroleptics (quetiapine and clozapine are allowed)

* Centrally active anti-hypertensive drugs (e.g., clonidine, alpha-methyldopa, guanidine, or guanfacine)

* Immunosuppressants or systemic corticosteroids \>10 mg/day prednisone or equivalent

* Anticoagulants

9\. History or presence of brain MRI scans indicative of a neurologic disease other than AD or any other significant abnormality.

10\. Subject has an atypical variant presentation of AD, if known from medical history, particularly non-amnestic AD.

11\. History of treatment for cancer within the past 2 years. Subjects who have undergone curative excision of basal cell carcinoma or squamous cell carcinoma of the skin within the past 2 years are permitted.

12\. Blood pressure and ECG parameters at Screening:

Seated systolic blood pressure \< 90 mmHg or \> 150 mmHg; or diastolic blood pressure \< 50 mmHg or \> 95 mmHg

ECG abnormalities on the screening ECG including: clinically significant conduction abnormalities, ischemic changes (e.g., prior Q-wave myocardial infarction and/or marked ischemic ST- and T-wave), arrhythmias (e.g., persistent or paroxysmal ventricular or supraventricular arrhythmias, including atrial fibrillation), or other ECG abnormalities that would pose unnecessary risk in the opinion of the Investigator

QTc interval \> 450 in males or \> 470 in females utilizing Fredericia's correction (QTcF)

13\. Abnormal stress ECG in relation to age at Screening.

14\. Renal insufficiency (serum creatinine \>177 μmol/L).

15\. Hepatic impairment with alanine aminotransferase or aspartate aminotransferase \> 1.5 times the upper limit of normal, or Child-Pugh class B or C.

16\. Hearing test result considered unacceptable for auditory ERP P300 assessment.

17\. Positive urine or serum pregnancy test, lactating, or plans to become pregnant during the trial.

18\. Significant suicide risk as assessed by C-SSRS.

19\. Any condition that in the judgement of the Investigator would interfere with the ability to complete the trial, pose significant risk to subject safety, or potentially confound interpretation of trial results, e.g., known issues with ability to swallow size 5 capsules.

Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of Oral ASN51 in Healthy Subjects and Subjects With Alzheimer's Disease

What this study is about

Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of Oral ASN51 in Healthy Subjects and Subjects With Alzheimer's Disease

What this study is about